---
schema_version: "secwatch.filing_event.v1"
accession: "0001731122-26-001333"
form_type: "8-K"
ticker: "LNAI"
cik: "0001527728"
company_name: "Lunai Bioworks Inc."
filed_at: "2026-10-09T18:00:32+00:00"
generated_at: "2026-10-12T15:13:28.122762+00:00"
event_type: "regulatory"
sentiment: "negative"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Lunai Bioworks asks Nasdaq to suspend LNAI trading amid Seven Points Capital litigation

## Summary
- On October 9, 2026, Lunai Bioworks submitted a formal request to Nasdaq to immediately suspend trading of its common stock, ticker LNAI.
- The request cites court-ordered discovery records in Lunai Bioworks, Inc. v. Seven Points Capital LLC et al., Case No. 1:26-cv-00549-CFC, D. Del.
- Submission describes substantial short selling, locate deficiencies, concentrated failures to deliver, and questions whether LNAI trading is fair and orderly.
- Lunai says Nasdaq has not yet decided; the request alone does not halt trading, and Nasdaq retains authority to suspend trading.
- Second Amended Complaint was filed August 26, 2026; litigation remains pending and allegations are not yet adjudicated, per the filing.

## SEC filing metadata
- accession: 0001731122-26-001333
- form_type: 8-K
- ticker: LNAI
- cik: 0001527728
- company_name: Lunai Bioworks Inc.
- filed_at: 2026-10-09T18:00:32+00:00
- event_type: regulatory
- sentiment: negative
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1527728/000173112226001333/0001731122-26-001333-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1527728/000173112226001333/e8001_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001731122-26-001333
- JSON: https://secwatch.observer/filing/0001731122-26-001333.json
- Plain text: https://secwatch.observer/filing/0001731122-26-001333.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.